Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.

ABSTRACT:

Importance

To date, single-agent programmed cell death 1 protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint blockade has shown limited activity in recurrent epithelial ovarian cancer. Combination strategies of PD-1/PD-L1 inhibition with antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a potential therapeutic opportunity in this disease.

Objective

To evaluate the activity of combined nivolumab and bevacizumab in women with relapsed ovarian cancer.

Design, setting, and participants

A single-arm, phase 2 study enrolled patients between February 8, 2017, and December 29, 2017, at 2 sites in the United States; the primary data analysis was completed July 27, 2018. Thirty-eight wome

SUBMITTER: Liu JF 

PROVIDER: S-EPMC6802049 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature